SecBot SecBot
SECBOTREPLAY Home › Report › SKYE

SKYE · Skye Bioscience reported Q4 and full-year 2025 financial results,…

Skye Bioscience, Inc. · PRESS-RELEASE filed Mar 10, 2026 at 16:01 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 10, 2026 at 16:01 ET

Skye Bioscience reported Q4 and full-year 2025 financial results, highlighting ongoing clinical progress with its obesity candidate nimacimab, including initiation of a higher-dose expansion study and FDA feedback shaping Phase 2b design. The company emphasized strong combination data with semaglutide, showing 22.3% mean weight loss at 52 weeks and favorable body composition outcomes, but reported a significant net loss increase due to higher R&D and manufacturing costs. Cash runway is expected through Q4 2026, excluding Phase 2b clinical costs.

  • Initiated higher-dose CBeyond Expansion Study (Part C) with 400 mg and 600 mg IV cohorts to assess safety and pharmacokinetics; topline data expected Q4 2026.
  • Received FDA Type C meeting feedback informing Phase 2b combination trial design with incretin therapy.
  • Interim 52-week data: 22.3% weight loss with nimacimab + semaglutide, no plateau observed, strong safety profile maintained.
  • 13-week off-treatment follow-up: combination cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone; maintained fat loss and gained lean mass.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access